Pfizer Inc
NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024
PFE Articles
It is very rare for a year to go exactly as analysts and investors might expect. After all, predicting a move a day or a week out is hard enough — and this is also an election year when the Federal...
Published:
Last Updated:
October 13, 2016: Markets opened lower Thursday following a weaker view on China’s trade balance joined with worries about the Fed and third-quarter earnings leave investors with the jitters. Citi,...
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
October 6, 2016: Markets opened slightly lower Thursday and tracked close to the break-even line for much of the day. Tomorrow’s report on non-farm payrolls for September is the week’s big data...
Published:
Last Updated:
September 29, 2016: Markets opened slightly higher again Thursday following Wednesday’s announced agreement among OPEC members to rein in production. Comments various Fed officials talking a rate...
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
Last Updated:
September 26, 2016: Markets opened lower again Monday and only the recently added real-estate sector traded higher on the day. Crude oil prices were up on hopes for an agreement this week on freezing...
Published:
Last Updated:
Pfizer shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies.
Published:
Last Updated:
While the polls have the race pretty tight, one thing is for sure: a victory by Donald Trump would favor a far different group of stocks than a victory by Hillary Clinton.
Published:
Last Updated:
The volatility in the markets have shaken some of the top dividend leaders and may be giving long-term investors a great buying opportunity.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
Published:
Last Updated: